DE69230112T2 - Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin - Google Patents

Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin

Info

Publication number
DE69230112T2
DE69230112T2 DE69230112T DE69230112T DE69230112T2 DE 69230112 T2 DE69230112 T2 DE 69230112T2 DE 69230112 T DE69230112 T DE 69230112T DE 69230112 T DE69230112 T DE 69230112T DE 69230112 T2 DE69230112 T2 DE 69230112T2
Authority
DE
Germany
Prior art keywords
carbamazepine
neurological
diseases
delivery system
drug delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69230112T
Other languages
English (en)
Other versions
DE69230112D1 (de
Inventor
Edward M Rudnic
George W Belendiuk
John Mccartty
Sandra Wassink
Richard A Couch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire LLC
Original Assignee
Shire Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24952109&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69230112(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Laboratories Inc filed Critical Shire Laboratories Inc
Application granted granted Critical
Publication of DE69230112D1 publication Critical patent/DE69230112D1/de
Publication of DE69230112T2 publication Critical patent/DE69230112T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
DE69230112T 1991-07-23 1992-07-23 Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin Expired - Lifetime DE69230112T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/734,541 US5326570A (en) 1991-07-23 1991-07-23 Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
PCT/US1992/006123 WO1993001804A1 (en) 1991-07-23 1992-07-23 Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine

Publications (2)

Publication Number Publication Date
DE69230112D1 DE69230112D1 (de) 1999-11-11
DE69230112T2 true DE69230112T2 (de) 2000-03-02

Family

ID=24952109

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69230112T Expired - Lifetime DE69230112T2 (de) 1991-07-23 1992-07-23 Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin

Country Status (10)

Country Link
US (2) US5326570A (de)
EP (1) EP0660705B1 (de)
JP (1) JP3806740B2 (de)
AT (1) ATE185268T1 (de)
CA (1) CA2114014C (de)
DE (1) DE69230112T2 (de)
DK (1) DK0660705T3 (de)
ES (1) ES2137948T3 (de)
GR (1) GR3031448T3 (de)
WO (1) WO1993001804A1 (de)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
WO1995003052A1 (en) * 1993-07-22 1995-02-02 Warner-Lambert Company Controlled release tacrine drug delivery systems and methods for preparing same
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US5952004A (en) * 1994-03-18 1999-09-14 Shire Laboratories Inc. Emulsified drug delivery systems
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5698210A (en) 1995-03-17 1997-12-16 Lee County Mosquito Control District Controlled delivery compositions and processes for treating organisms in a column of water or on land
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6572880B2 (en) 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
WO1998029095A2 (en) * 1997-01-03 1998-07-09 Elan Corporation, Plc Sustained release cisapride mini-tablet formulation
US5848966A (en) * 1997-03-04 1998-12-15 Graphic Controls Corporation Medical device easily removed from skin and a method of removal therefrom
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
DE19724696A1 (de) * 1997-06-12 1998-12-24 Hexal Ag Pharmazeutische Zubereitung mit drei Pelletarten
AU5155198A (en) * 1997-08-28 1999-03-22 Robert Murdock Method and composition for transdermal administration of pharmacologic agent
FR2771292B1 (fr) * 1997-11-21 2000-02-18 Ethypharm Lab Prod Ethiques Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
DE19809719A1 (de) * 1998-03-06 1999-09-09 Roehm Gmbh Wäßrige Dispersion geeignet zur Herstellung von Überzugs- und Bindemitteln für feste orale Arzneiformen
US6211194B1 (en) * 1998-04-30 2001-04-03 Duke University Solution containing nicotine
US6365183B1 (en) 1998-05-07 2002-04-02 Alza Corporation Method of fabricating a banded prolonged release active agent dosage form
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6706282B1 (en) * 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6162466A (en) * 1999-04-15 2000-12-19 Taro Pharmaceutical Industries Ltd. Sustained release formulation of carbamazepine
CA2380333A1 (en) * 1999-08-26 2001-03-01 Christian Andina Pharmaceutical formulations
WO2001062231A1 (en) * 2000-02-24 2001-08-30 Advancis Pharmaceutical Corporation Antibiotic composition with inhibitor
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
AU2001239838A1 (en) * 2000-02-24 2001-09-03 Advancis Pharmaceutical Corporation Therapeutic product, use and formulation thereof
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
AU2001239841B2 (en) * 2000-02-24 2006-04-27 Shionogi, Inc. Antibiotic and antifungal compositions
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US6524617B1 (en) * 2001-07-25 2003-02-25 Isp Investments Inc. Synergistic filler composition
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
US20040146559A1 (en) * 2002-09-28 2004-07-29 Sowden Harry S. Dosage forms having an inner core and outer shell with different shapes
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
MXPA04002980A (es) * 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosificacion que tienen un nucleo interior y coraza exterior con diferentes formas.
US20030228368A1 (en) * 2001-09-28 2003-12-11 David Wynn Edible solid composition and dosage form
US20040253312A1 (en) * 2001-09-28 2004-12-16 Sowden Harry S. Immediate release dosage form comprising shell having openings therein
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
CA2478121A1 (en) * 2002-03-07 2003-09-18 Advancis Pharmaceutical Corporation Antibiotic composition
US6572889B1 (en) * 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
EP1499300B1 (de) * 2002-04-29 2009-03-18 Supernus Pharmaceuticals, Inc. Pharmazeutische formulierungen mit verbesserter bioverfügbarkeit
MXPA04011801A (es) * 2002-05-31 2005-09-12 Desitin Arzneimittel Gmbh Composicion farmaceutica que contiene oxcarbazepina con liberacion controlada de la substancia activa.
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
US20040086569A1 (en) * 2002-08-13 2004-05-06 Medtronic, Inc. Active agent delivery systems, medical devices, and methods
WO2004014448A1 (en) * 2002-08-13 2004-02-19 Medtronic, Inc. Active agent delivery system including a hydrophilic polymer, medical device, and method
US20040039437A1 (en) * 2002-08-13 2004-02-26 Medtronic, Inc. Medical device exhibiting improved adhesion between polymeric coating and substrate
WO2004014449A1 (en) * 2002-08-13 2004-02-19 Medtronic, Inc. Active agent delivery system including a polyurethane, medical device, and method
DE60316579T2 (de) * 2002-08-13 2008-07-03 Medtronic, Inc., Minneapolis System zur abgabe von wirkstoffen mit einem hydrophoben cellulose-derivat
US7807197B2 (en) * 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
DK1803444T3 (en) 2002-12-20 2019-02-25 Niconovum Ab PROCEDURE FOR PREPARING A NICOTIC PARTICULATE MATERIAL WITH A CRYSTALLINE CELLULOSE (ESPECIALLY MCC)
JP3811127B2 (ja) * 2003-01-30 2006-08-16 株式会社東芝 情報記録装置及び情報記録方法
WO2005009364A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2533292C (en) * 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
US20050064005A1 (en) * 2003-08-13 2005-03-24 Dinh Thomas Q. Active agent delivery systems including a miscible polymer blend, medical devices, and methods
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
JP2007505129A (ja) * 2003-09-11 2007-03-08 グリュコン テクノロジーズ グループ エルエルシー （−）−ヒドロキシクエン酸の腸溶性送達物
EP1663169A4 (de) * 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In Antibiotisches produkt, seine verwendung und formulierung
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US20050074514A1 (en) * 2003-10-02 2005-04-07 Anderson Oliver B. Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms
EP1679066A4 (de) * 2003-10-27 2011-06-22 Astellas Pharma Inc Arzneimittelhaltiges beschichtes mikroteilchen für eine im mund zerfallende tablette
JP5610663B2 (ja) 2003-11-04 2014-10-22 スパーナス ファーマシューティカルズ インコーポレイテッド トロスピウムの１日１回剤形
WO2005046663A1 (en) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Compositions of quaternary ammonium containing bioavailability enhancers
JP5072364B2 (ja) 2003-11-25 2012-11-14 スミスクライン ビーチャム （コーク） リミテッド カルベジロール遊離塩基、カルベジロール塩、無水形態またはその溶媒和物、対応する医薬組成物、制御放出処方および治療またはデリバリー方法
CA2452588C (en) * 2003-12-08 2015-05-19 Shire Pharmaceutical Development Inc. Methods for the treatment of bipolar disorder using carbamazepine
US20060094709A1 (en) * 2003-12-08 2006-05-04 Kalali Amir H Methods for the treatment of bipolar disorder using carbamazepine
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US8067029B2 (en) * 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
US20070190133A1 (en) * 2004-10-27 2007-08-16 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088587A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070281022A1 (en) * 2004-10-27 2007-12-06 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8383159B2 (en) * 2004-10-27 2013-02-26 Mcneil-Ppc, Inc. Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088593A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088586A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060087051A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
BRPI0518483A2 (pt) 2004-11-23 2008-11-18 Neuromolecular Pharmaceuticals Inc composiÇço compreendendo uma matriz ou revestimento de liberaÇço controlada e um antagonista de receptor de nmda, mÉtodo para administraÇço de tal antagonista de nmda a um paciente
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1845968A2 (de) 2004-11-24 2007-10-24 Neuromolecular Pharmaceuticals, Inc Zusammensetzung mit einem nmda-rezeptor-antagonisten und levodopa und ihre verwendung zur behandlung von neurologischen erkrankungen
US20060127421A1 (en) * 2004-12-09 2006-06-15 Celgene Corporation Treatment using D-threo methylphenidate
CN101132780A (zh) * 2005-02-15 2008-02-27 爵士制药公司 缓慢释放取代的吡嗪化合物的剂型和方法
US20090169619A1 (en) * 2005-02-25 2009-07-02 Corepharma Llc Carbamazepine extended release dosage form
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
MX2007013327A (es) * 2005-04-25 2008-04-21 Teva Pharma Formulaciones de liberacion prolongada.
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
US20070071819A1 (en) * 2005-05-30 2007-03-29 Kesarwani Amit K Multiple unit modified release compositions of carbamazepine and process for their preparation
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20070077300A1 (en) * 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
WO2007104573A2 (en) * 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
WO2007112579A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Drug delivery composition
AU2013200237B2 (en) * 2006-04-26 2015-07-16 Supernus Pharmaceuticals, Inc. Controlled released preparations of oxcarbazepine having sigmoidal release profile
EP2359830B1 (de) * 2006-04-26 2012-09-19 Supernus Pharmaceuticals, Inc. Oxcarbazepinpräparate für kontrollierte Freisetzung mit sigmoidalem Freisetzungsprofil
EP2018157A2 (de) * 2006-04-26 2009-01-28 Astron Research Limited Antiepileptika enthaltende formulierung mit kontrollierter freisetzung
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
JP2010504931A (ja) * 2006-09-27 2010-02-18 ニコノヴァム エービー 指向性の使用
AU2007309281B2 (en) * 2006-10-20 2013-10-31 Johnson & Johnson Consumer Inc. Acetaminophen / ibuprofen combinations
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
AU2007319141B2 (en) 2006-11-17 2013-01-10 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
US20080317677A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
US20080317678A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
US20090060983A1 (en) * 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
US20110091566A1 (en) * 2007-09-25 2011-04-21 Nirmal Mulye Controlled release pharmaceutical compositions
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
US20090110716A1 (en) * 2007-10-31 2009-04-30 Frank Bunick Orally disintegrative dosage form
US20090143362A1 (en) * 2007-12-04 2009-06-04 Barabde Umesh Vinayakrao Carbamazepine formulations
CN101917975B (zh) * 2007-12-21 2013-05-08 麦克内尔-Ppc股份有限公司 片剂的制造
WO2009087690A2 (en) * 2008-01-11 2009-07-16 Jubilant Organosys Limited Multiparticulate extended release pharmaceutical composition of carbamazepine and process for manufacturing the same
EP2309999A1 (de) * 2008-06-26 2011-04-20 McNeil-PPC, Inc. Pharmazeutische wirkstoffe enthaltende beschichtete teilchen
WO2010015029A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
CA2736531C (en) * 2008-09-17 2016-10-25 Niconovum Ab Process for preparing snuff composition
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
US8784781B2 (en) * 2009-09-24 2014-07-22 Mcneil-Ppc, Inc. Manufacture of chewing gum product with radiofrequency
US20110070286A1 (en) * 2009-09-24 2011-03-24 Andreas Hugerth Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
US8858210B2 (en) 2009-09-24 2014-10-14 Mcneil-Ppc, Inc. Manufacture of variable density dosage forms utilizing radiofrequency energy
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
CN102883601A (zh) * 2009-12-02 2013-01-16 阿达玛斯医药公司 金刚烷胺组合物及其使用方法
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
WO2013054178A2 (en) * 2011-10-14 2013-04-18 Micro Labs Limited Extended release pharmaceutical compositions containing carmabazepine
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US20150133516A1 (en) 2013-11-13 2015-05-14 Brian K. Adams Methods and Compositions for Treating ADHD
ES2750323T3 (es) 2014-01-10 2020-03-25 Johnson & Johnson Consumer Inc Método para la fabricación de un comprimido mediante radiofrecuencia y partículas recubiertas con pérdida
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2017004526A1 (en) 2015-07-02 2017-01-05 University Of Louisville Research Foundation, Inc. EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER
MA43532A (fr) 2015-12-30 2018-11-07 Adamas Pharmaceuticals Inc Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
CA3107139C (en) * 2018-09-21 2023-01-03 Kashiv Biosciences, Llc Extended release compositions comprising trihexyphenidyl
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
ATE72111T1 (de) * 1987-01-14 1992-02-15 Ciba Geigy Ag Therapeutisches system fuer schwerloesliche wirkstoffe.
DE3702029A1 (de) * 1987-01-24 1988-08-04 Basf Ag Waessriges oder pulverfoermiges, wasserdispergierbares praeparat eines in wasser schwerloeslichen pharmazeutischen wirkstoffs und verfahren zu seiner herstellung
US5009894A (en) * 1988-03-07 1991-04-23 Baker Cummins Pharmaceuticals, Inc. Arrangement for and method of administering a pharmaceutical preparation
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
US4942182A (en) * 1989-03-01 1990-07-17 Weiss Susan R B Treatment for cocaine addiction
US5023272A (en) * 1989-06-23 1991-06-11 Norwich Eaton Pharmaceuticals, Inc. Use of 5-phenyl-2-furan esters and amides as antiepileptic agents
US5284662A (en) * 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine

Also Published As

Publication number Publication date
EP0660705B1 (de) 1999-10-06
EP0660705A4 (de) 1994-10-20
GR3031448T3 (en) 2000-01-31
WO1993001804A1 (en) 1993-02-04
JP3806740B2 (ja) 2006-08-09
CA2114014C (en) 1999-05-11
JPH06511484A (ja) 1994-12-22
DK0660705T3 (da) 1999-12-20
US5912013A (en) 1999-06-15
CA2114014A1 (en) 1993-01-24
US5326570A (en) 1994-07-05
ATE185268T1 (de) 1999-10-15
ES2137948T3 (es) 2000-01-01
EP0660705A1 (de) 1995-07-05
DE69230112D1 (de) 1999-11-11

Similar Documents

Publication Publication Date Title
DE69230112T2 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
HK1048058A1 (zh) 肝臟選擇性的藥用活性物
EP0740650A4 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
DE68929388T2 (de) Aus Harn isolierte antikoagulierende Verbindung
DE69914084D1 (de) Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen
DE59508961D1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE3650368D1 (de) Verwendung von Depogen zur Behandlung von eingeschränktem Blutkreislauf.
KR890007737A (ko) 진토작용을 하는 약제
RU98109592A (ru) Применение белка s-100b в лекарственных средствах и лекарственные средства, содержащие белок s-100b
IL103499A0 (en) Pharmaceutical compositions for treating anxiety in benzodiazepine withdrawn patients
UA29106A (uk) Спосіб лікування вібраційної хвороби
UA29910A (uk) Спосіб лікування дисфункції скоренево- нижньощелепного суглоба
UA27060C2 (uk) Спосіб стимулюваhhя зовhішhьої секреції підшлуhкової залози
MX9800686A (es) Nueva proteina hmw humana mp52s.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SHIRE LLC, FLORENCE, KY., US

R071 Expiry of right

Ref document number: 660705

Country of ref document: EP